|
rs1057519847
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, patients with EGFR 19del and LM showed marginally significantly shorter OS (P = .0531) and patients with EGFR L858R and LM had OS similar to that of patients without LM (P = .1883).
|
28549835 |
2017 |
|
rs1057519848
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, patients with EGFR 19del and LM showed marginally significantly shorter OS (P = .0531) and patients with EGFR L858R and LM had OS similar to that of patients without LM (P = .1883).
|
28549835 |
2017 |
|
rs121434568
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, patients with EGFR 19del and LM showed marginally significantly shorter OS (P = .0531) and patients with EGFR L858R and LM had OS similar to that of patients without LM (P = .1883).
|
28549835 |
2017 |
|
rs121913247
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Finally, a <i>MET</i>ex14 del mutation-positive NSCLC patient who responded to crizotinib but later relapsed, demonstrated a mixed response to glesatinib including reduction in size of a <i>MET</i> Y1230H mutation-positive liver metastasis and concurrent loss of detection of this mutation in plasma DNA.<b>Conclusions:</b> Together, these data demonstrate that glesatinib exhibits a distinct mechanism of target inhibition and can overcome resistance to type I MET inhibitors.<i></i>.
|
28765324 |
2017 |
|
rs121913250
|
|
|
0.010 |
GeneticVariation |
BEFREE |
KRAS c.34G>A mutation was detected in primary tumor and liver metastasis, which additionally revealed 2 rare PI3KCA mutations (c.1633G>C and c.1645G>C).
|
29409955 |
2018 |
|
rs121913530
|
|
|
0.010 |
GeneticVariation |
BEFREE |
KRAS c.34G>A mutation was detected in primary tumor and liver metastasis, which additionally revealed 2 rare PI3KCA mutations (c.1633G>C and c.1645G>C).
|
29409955 |
2018 |
|
rs765433422
|
|
|
0.010 |
GeneticVariation |
BEFREE |
KRAS c.34G>A mutation was detected in primary tumor and liver metastasis, which additionally revealed 2 rare PI3KCA mutations (c.1633G>C and c.1645G>C).
|
29409955 |
2018 |
|
rs121434569
|
|
|
0.020 |
GeneticVariation |
BEFREE |
First-line gefitinib, longer EGFR TKI treatment duration, male, initial liver metastasis and uncommon EGFR mutations may be independent factors for secondary EGFR T790M mutation.
|
30485437 |
2019 |
|
rs113488022
|
|
|
0.010 |
GeneticVariation |
BEFREE |
BRAF V600E and SRC mutations were mutually exclusive, and SRC mutation was significantly associated with left-sided tumor and liver metastasis compared to BRAF V600E mutation (P = 0.016 and P = 0.025, respectively).
|
30792536 |
2019 |
|
rs121913377
|
|
|
0.010 |
GeneticVariation |
BEFREE |
BRAF V600E and SRC mutations were mutually exclusive, and SRC mutation was significantly associated with left-sided tumor and liver metastasis compared to BRAF V600E mutation (P = 0.016 and P = 0.025, respectively).
|
30792536 |
2019 |